Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion

Oncology Reports

Volumn 35, Issue 1, 2016, Pages 546-551

  You, Bo Ra ^a   Park, Woo Hyun ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Auranofin; Glutathione; Mesothelioma; Reactive oxygen species; Thioredoxin reductas

Indexed keywords

ACETYLCYSTEINE; AURANOFIN; BUTHIONINE SULFOXIMINE; GLUTATHIONE; LACTATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE 1; CASPASE; TXNRD1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DEPLETION; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MESOTHELIOMA; MESOTHELIOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; AURANOFIN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; MESOTHELIOMA; OXIDATIVE STRESS; THIOREDOXIN REDUCTASE 1;

EID: 84954047445     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4382     Document Type: Article

References (32)

1. Lu J and Holmgren A: The thioredoxin antioxidant system. Free Radic Biol Med 66: 75-87, 2014.
2. Chen B, Nelin VE, Locy ML, Jin Y and Tipple TE: Thioredoxin-1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol Physiol 305: L389-L395, 2013.
3. Bobba A, Casalino E, Petragallo VA and Atlante A: Thioredoxin/thioredoxin reductase system involvement in cerebellar granule cell apoptosis. Apoptosis 19: 1497-1508, 2014.
4. Laborde E: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 17: 1373-1380, 2010.
5. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M, Schumann A, et al: Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 12: R44, 2010.
6. Iwasawa S, Yamano Y, Takiguchi Y, Tanzawa H, Tatsumi K and Uzawa K: Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinoma. Oncol Rep 25: 637-644, 2011.
7. Fu JN, Li J, Tan Q, Yin HW, Xiong K, Wang TY, Ren XY and Zeng HH: Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Invest New Drugs 29: 627-636, 2011.
8. Lin T, Ding Z, Li N, Xu J, Luo G, Liu J and Shen J: 2-Tellurium-bridged β-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression. Carcinogenesis 32: 154-167, 2011.
9. Liang YW, Zheng J, Li X, Zheng W and Chen T: Selenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cells. Eur J Med Chem 84: 335-342, 2014.
10. Kiebala M, Skalska J, Casulo C, Brookes PS, Peterson DR, Hilchey SP, Dai Y, Grant S, Maggirwar SB and Bernstein SH: Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach. Exp Hematol 43: 89-99, 2015.
11. Isakov E, Weisman-Shomer P and Benhar M: Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin. Biochim Biophys Acta 1840: 3153-3161, 2014.
12. Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, Liu S, Song W, Lu X, Lan X, et al: Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 5: 5453-5471, 2014.
13. Park SH, Lee JH, Berek JS and Hu MC: Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int J Oncol 45: 1691-1698, 2014.
14. Fan C, Zheng W, Fu X, Li X, Wong YS and Chen T: Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis 5: e1191, 2014.
15. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H and Kwon ED: B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 9: 1036-1040, 2014.
16. Kahlos K, Soini Y, Säily M, Koistinen P, Kakko S, Pääkkö P, Holmgren A and Kinnula VL: Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95: 198-204, 2001.
17. Han S, Kim K, Kim H, Kwon J, Lee YH, Lee CK, Song Y, Lee SJ, Ha N and Kim K: Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages. Arch Pharm Res 31: 67-74, 2008.
18. Suarez-Almazor ME, Spooner CH, Belseck E and Shea B: Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst Rev 2: CD002048, 2000.
19. Kim NH, Park HJ, Oh MK and Kim IS: Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep 46: 59-64, 2013.
20. Park N and Chun YJ: Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J Toxicol Environ Health A 77: 1467-1476, 2014.
21. Papaioannou M, Mylonas I, Kast RE and Brüning A: Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. Oncoscience 1: 21-29, 2014.
22. Lincoln DT, Al-Yatama F, Mohammed FM, Al-Banaw AG, Al-Bader M, Burge M, Sinowatz F and Singal PK: Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. Anticancer Res 30: 767-775, 2010.
23. Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L and Arnér ES: High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med 47: 1661-1671, 2009.
24. Ferrer MD, Sureda A, Tauler P, Palacín C, Tur JA and Pons A: Impaired lymphocyte mitochondrial antioxidant defences in variegate porphyria are accompanied by more inducible reactive oxygen species production and DNA damage. Br J Haematol 149: 759-767, 2010.
25. Scarbrough PM, Mapuskar KA, Mattson DM, Gius D, Watson WH and Spitz DR: Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med 52: 436-443, 2012.
26. Lopert P, Day BJ and Patel M: Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS One 7: e50683, 2012.
27. Dunning S, Ur Rehman A, Tiebosch MH, Hannivoort RA, Haijer FW, Woudenberg J, van den Heuvel FA, Buist-Homan M, Faber KN and Moshage H: Glutathione and antioxidant enzymes serve complementary roles in protecting activated hepatic stellate cells against hydrogen peroxide-induced cell death. Biochim Biophys Acta 1832: 2027-2034, 2013.
28. Iversen R, Andersen PA, Jensen KS, Winther JR and Sigurskjold BW: Thiol-disulfide exchange between glutaredoxin and glutathione. Biochemistry 49: 810-820, 2010.
29. Kumar C, Igbaria A, D'Autreaux B, Planson AG, Junot C, Godat E, Bachhawat AK, Delaunay-Moisan A and Toledano MB: Glutathione revisited: A vital function in iron metabolism and ancillary role in thiol-redox control. EMBO J 30: 2044-2056, 2011.
30. Schoeneberger H, Belz K, Schenk B and Fulda S: Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death. Oncogene 34: 4032-4043, 2015.
31. Buşu C, Li W, Caldito G and Aw TY: Inhibition of glutathione synthesis in brain endothelial cells lengthens S-phase transit time in the cell cycle: Implications for proliferation in recovery from oxidative stress and endothelial cell damage. Redox Biol 1: 131-139, 2013.
32. Hall MD, Marshall TS, Kwit AD, Miller Jenkins LM, Dulcey AE, Madigan JP, Pluchino KM, Goldsborough AS, Brimacombe KR, Griffiths GL, et al: Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin. J Biol Chem 289: 21473-21489, 2014.